594 related articles for article (PubMed ID: 34486476)
21. Profiles of immune infiltration in lung adenocarcinoma and their clinical significant: A gene-expression-based retrospective study.
Chen G; Dong Z; Wu D; Chen Y
J Cell Biochem; 2020 Nov; 121(11):4431-4439. PubMed ID: 32003059
[TBL] [Abstract][Full Text] [Related]
22. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma.
Wang F; Lin H; Su Q; Li C
World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740
[TBL] [Abstract][Full Text] [Related]
23. A Seven-Gene Signature with Close Immune Correlation Was Identified for Survival Prediction of Lung Adenocarcinoma.
Zou X; Hu Z; Huang C; Chang J
Med Sci Monit; 2020 Jul; 26():e924269. PubMed ID: 32613949
[TBL] [Abstract][Full Text] [Related]
24. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
Front Immunol; 2022; 13():891175. PubMed ID: 35990668
[TBL] [Abstract][Full Text] [Related]
25. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
26. Predictions of the dysregulated competing endogenous RNA signature involved in the progression of human lung adenocarcinoma.
Yang D; He Y; Wu B; Liu R; Wang N; Wang T; Luo Y; Li Y; Liu Y
Cancer Biomark; 2020; 29(3):399-416. PubMed ID: 32741804
[TBL] [Abstract][Full Text] [Related]
27. A novel prognostic signature of immune-related lncRNA pairs in lung adenocarcinoma.
Liu Y; Wu Q; Fan X; Li W; Li X; Zhu H; Zhou Q; Yu J
Sci Rep; 2021 Aug; 11(1):16794. PubMed ID: 34408216
[TBL] [Abstract][Full Text] [Related]
28. A novel autophagy-related lncRNA survival model for lung adenocarcinoma.
Wu L; Wen Z; Song Y; Wang L
J Cell Mol Med; 2021 Jun; 25(12):5681-5690. PubMed ID: 33987935
[TBL] [Abstract][Full Text] [Related]
29. Unique metastasis-associated lncRNA signature optimizes prediction of tumor relapse in lung adenocarcinoma.
Zhang X; Han J; Du L; Li X; Hao J; Wang L; Zheng G; Duan W; Xie Y; Zhao Y; Zhang X; Zou M; Wang C
Thorac Cancer; 2020 Mar; 11(3):728-737. PubMed ID: 31994347
[TBL] [Abstract][Full Text] [Related]
30. A pyroptosis-related lncRNA signature predicts prognosis and immune microenvironment in head and neck squamous cell carcinoma.
Zhu W; Ye Z; Chen L; Liang H; Cai Q
Int Immunopharmacol; 2021 Dec; 101(Pt B):108268. PubMed ID: 34688154
[TBL] [Abstract][Full Text] [Related]
31. Construction and validation of a cuproptosis-related lncRNA signature for the prediction of the prognosis of LUAD and LUSC.
Wang Y; Xiao X; Li Y
Sci Rep; 2023 Feb; 13(1):2477. PubMed ID: 36774418
[TBL] [Abstract][Full Text] [Related]
32. Relationships of N6-Methyladenosine-Related Long Non-Coding RNAs With Tumor Immune Microenvironment and Clinical Prognosis in Lung Adenocarcinoma.
Zhao J; Lin X; Zhuang J; He F
Front Genet; 2021; 12():714697. PubMed ID: 34777460
[No Abstract] [Full Text] [Related]
33. Construction of RNA Methylation Modification-immune-related lncRNA Molecular Subtypes and Prognostic Scoring System in Lung Adenocarcinoma.
Wang J; Shu J
Curr Med Chem; 2024; 31(12):1539-1560. PubMed ID: 37680151
[TBL] [Abstract][Full Text] [Related]
34. Novel chemokine related LncRNA signature correlates with the prognosis, immune landscape, and therapeutic sensitivity of esophageal squamous cell cancer.
Zhang Z; Wang J; Han W; Zhao L
BMC Gastroenterol; 2023 Apr; 23(1):132. PubMed ID: 37081402
[TBL] [Abstract][Full Text] [Related]
35. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
Wu P; Zheng Y; Wang Y; Wang Y; Liang N
J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
[TBL] [Abstract][Full Text] [Related]
36. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
Zuo S; Wei M; Wang S; Dong J; Wei J
Front Immunol; 2020; 11():1218. PubMed ID: 32714316
[No Abstract] [Full Text] [Related]
37. Establishment of a prognostic signature for lung adenocarcinoma using cuproptosis-related lncRNAs.
Yalimaimaiti S; Liang X; Zhao H; Dou H; Liu W; Yang Y; Ning L
BMC Bioinformatics; 2023 Mar; 24(1):81. PubMed ID: 36879187
[TBL] [Abstract][Full Text] [Related]
38. Development and validation of an immune-related prognostic signature in lung adenocarcinoma.
Sun S; Guo W; Wang Z; Wang X; Zhang G; Zhang H; Li R; Gao Y; Qiu B; Tan F; Gao Y; Xue Q; Gao S; He J
Cancer Med; 2020 Aug; 9(16):5960-5975. PubMed ID: 32592319
[TBL] [Abstract][Full Text] [Related]
39. Exploration of the prognostic signature reflecting tumor microenvironment of lung adenocarcinoma based on immunologically relevant genes.
Wu W; Jia L; Zhang Y; Zhao J; Dong Y; Qiang Y
Bioengineered; 2021 Dec; 12(1):7417-7431. PubMed ID: 34612148
[TBL] [Abstract][Full Text] [Related]
40. Construction of a novel immune-related lncRNA signature and its potential to predict the immune status of patients with hepatocellular carcinoma.
Deng M; Lin JB; Zhao RC; Li SH; Lin WP; Zou JW; Wei W; Guo RP
BMC Cancer; 2021 Dec; 21(1):1347. PubMed ID: 34923955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
